{"id":53614,"date":"2023-09-20T09:48:35","date_gmt":"2023-09-20T09:48:35","guid":{"rendered":"https:\/\/medsname.com\/febutaz\/"},"modified":"2026-04-30T10:25:11","modified_gmt":"2026-04-30T10:25:11","slug":"febutaz","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/febutaz\/","title":{"rendered":"Febutaz"},"content":{"rendered":"

<\/p>\n

\n

\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Febutaz<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 febuxostat 40 mg \/ 80 mg<\/strong> made by Sun Pharma. It is used for long-term lowering of serum uric acid in adults with chronic gout (urate-lowering therapy) — including those with urate kidney stones. Take exactly as directed by your clinician \u2014 do not adjust the dose yourself.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\ud83d\udd12 \u039a\u03c1\u03c5\u03c0\u03c4\u03bf\u03b3\u03c1\u03b1\u03c6\u03b7\u03bc\u03ad\u03bd\u03b7 \u039f\u03bb\u03bf\u03ba\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 \u0391\u03b3\u03bf\u03c1\u03ac\u03c2<\/strong> \u00b7 \ud83d\udcb3 \u0395\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf\u03c2 \u0395\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae\u03c2<\/strong> \u00b7 \ud83d\ude9a \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u0391\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/strong> \u00b7 \u2b50 4.9\/5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2<\/strong><\/div>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03c4\u03af\u03b4\u03b1 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ad\u03bd\u03b1 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/strong>. \u039f\u03b9 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b5\u03c2 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03bc\u03c0\u03bf\u03c1\u03b9\u03ba\u03ae \u03c3\u03ae\u03bc\u03b1\u03bd\u03c3\u03b7 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5\u03c2 \u03c3\u03c5\u03bd\u03b5\u03c1\u03b3\u03ac\u03c4\u03b5\u03c2 \u03bc\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>. \u0388\u03c7\u03bf\u03c5\u03bc\u03b5 \u03b5\u03be\u03c5\u03c0\u03b7\u03c1\u03b5\u03c4\u03ae\u03c3\u03b5\u03b9 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf\u03c5\u03c2 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2<\/strong> \u03bc\u03b5 4.9\/5 \u03bc\u03ad\u03c3\u03bf \u03cc\u03c1\u03bf \u03b1\u03be\u03b9\u03bf\u03bb\u03cc\u03b3\u03b7\u03c3\u03b7\u03c2<\/strong> \u03c3\u03b5 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b1 \u03b1\u03c0\u03cc 600 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1.<\/p>\n

\n

⚠ Cardiovascular caution — allopurinol is the preferred first-line urate lowering therapy<\/strong><\/p>\n

The 2018 CARES trial<\/strong> showed higher cardiovascular and all-cause mortality on febuxostat versus allopurinol in patients with gout AND established cardiovascular disease. The 2020 FAST trial<\/strong> found no excess in a European population. Major guidelines (ACR 2020, EULAR 2016) recommend allopurinol as first-line<\/strong>; febuxostat is reserved for patients who cannot tolerate or do not reach target on allopurinol, or who have HLA-B*5801 contraindications. Discuss cardiovascular history with your prescriber before starting.<\/p>\n<\/div>\n

What Febutaz is and how it works<\/h2>\n

Febutaz contains febuxostat<\/strong>, \u03ad\u03bd\u03b1 non-purine selective xanthine oxidase inhibitor<\/strong>. By blocking xanthine oxidase, it stops the conversion of hypoxanthine and xanthine to uric acid, lowering serum urate. Unlike allopurinol (a purine analogue), febuxostat is metabolised mostly in the liver, so it can be used in mild-to-moderate renal impairment without dose adjustment.<\/p>\n

Febutaz is licensed for the chronic management of hyperuricaemia in patients with gout<\/strong>, including tophaceous gout. It is not a treatment for an acute gout flare; flares are managed with NSAIDs, colchicine or corticosteroids.<\/p>\n

\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03cc\u03c0\u03bf\u03c2 \u03c7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7\u03c2<\/h2>\n\n\n\n\n\n\n\n\n\n
\u039f\u03bc\u03ac\u03b4\u03b1 \u03b1\u03c3\u03b8\u03b5\u03bd\u03ce\u03bd<\/th>\n\u03a3\u03c5\u03bd\u03b9\u03c3\u03c4\u03ce\u03bc\u03b5\u03bd\u03b7 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/th>\n<\/tr>\n<\/thead>\n
Adults with chronic gout — starting dose<\/td>\n40 mg \u03bc\u03af\u03b1 \u03c6\u03bf\u03c1\u03ac \u03b7\u03bc\u03b5\u03c1\u03b7\u03c3\u03af\u03c9\u03c2<\/strong><\/td>\n<\/tr>\n
Step-up after 2–4 weeks if serum urate > 0.36 mmol\/L (6 mg\/dL)<\/td>\n\u0391\u03cd\u03be\u03b7\u03c3\u03b7 \u03c3\u03b5 80 mg once daily<\/strong><\/td>\n<\/tr>\n
\u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03bd\u03b5\u03c6\u03c1\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 (eGFR <30)<\/td>\nUse cautiously; data limited; consider alternative<\/td>\n<\/tr>\n
\u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03b7\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 (Child-Pugh C)<\/td>\nAvoid — not studied<\/td>\n<\/tr>\n
Tophaceous gout \/ very high baseline urate<\/td>\nMay need 80 mg from start under specialist supervision<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Take at the same time each day, with or without food.<\/strong> Continue indefinitely — gout is a chronic condition. Target serum urate is usually < 0.36 mmol\/L (< 6 mg\/dL)<\/strong>; for tophaceous gout, < 0.30 mmol\/L (< 5 mg\/dL) for tophus dissolution.<\/p>\n

\n

✅ Co-prescribe acute-flare prophylaxis for the first 6 months<\/strong><\/p>\n

Starting any urate-lowering therapy can trigger gout flares<\/strong> as crystals shed from joints. ACR and EULAR guidelines recommend prophylactic colchicine 0.5–1 mg\/day<\/strong> \u03ae NSAID<\/strong> for at least 3–6 months when starting febuxostat — do not stop the febuxostat if a flare occurs.<\/p>\n<\/div>\n

\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b1<\/th>\n\u03a3\u03c5\u03c7\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
Gout flare (early therapy)<\/td>\nVery common in first 6 months<\/td>\nUse prophylaxis; do not stop febuxostat<\/td>\n<\/tr>\n
Liver enzyme rise<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\nCheck LFTs at baseline, 2 months, then periodically<\/td>\n<\/tr>\n
\u039a\u03b5\u03c6\u03b1\u03bb\u03b1\u03bb\u03b3\u03af\u03b1<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\nUsually mild<\/td>\n<\/tr>\n
Diarrhoea, nausea<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\n\u03a0\u03ac\u03c1\u03c4\u03b5 \u03bc\u03b5 \u03c6\u03b1\u03b3\u03b7\u03c4\u03cc<\/td>\n<\/tr>\n
\u0395\u03be\u03ac\u03bd\u03b8\u03b7\u03bc\u03b1<\/td>\n\u0391\u03c3\u03c5\u03bd\u03ae\u03b8\u03b9\u03c3\u03c4\u03b5\u03c2<\/td>\nStop if widespread; rare reports of severe cutaneous reactions<\/td>\n<\/tr>\n
Cardiovascular events (in established CVD)<\/td>\nCARES signal<\/td>\nDiscuss with cardiologist; consider allopurinol<\/td>\n<\/tr>\n
Hepatotoxicity (severe)<\/td>\n\u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nStop and seek review<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n\n\n\n\n\n\n\n\n\n
\u03a3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc\u03c2<\/th>\n\u0391\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1<\/th>\n\u0394\u03c1\u03ac\u03c3\u03b7<\/th>\n<\/tr>\n<\/thead>\n
Azathioprine, mercaptopurine<\/td>\nMajor rise in 6-mercaptopurine levels — bone-marrow toxicity<\/td>\n\u0391\u03c0\u03bf\u03c6\u03cd\u03b3\u03b5\u03c4\u03b5 \u03c3\u03c5\u03bd\u03b4\u03c5\u03b1\u03c3\u03bc\u03cc<\/strong><\/td>\n<\/tr>\n
\u0398\u03b5\u03bf\u03c6\u03c5\u03bb\u03bb\u03af\u03bd\u03b7<\/td>\nTheophylline levels may rise<\/td>\n\u03a0\u03b1\u03c1\u03b1\u03ba\u03bf\u03bb\u03bf\u03cd\u03b8\u03b7\u03c3\u03b7<\/td>\n<\/tr>\n
NSAIDs, colchicine, low-dose aspirin<\/td>\nUsed together for flare prophylaxis — standard pattern<\/td>\nNot a true interaction; co-prescribe<\/td>\n<\/tr>\n
Diuretics (thiazide, loop)<\/td>\nRaise serum urate — may need higher febuxostat dose<\/td>\nMonitor target urate level<\/td>\n<\/tr>\n
\u0392\u03b1\u03c1\u03c6\u03b1\u03c1\u03af\u03bd\u03b7<\/td>\nNo clinically significant interaction<\/td>\nStandard INR monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who should not take Febutaz<\/h2>\n